Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa
Abstract Multidrug resistant (MDR) P. aeruginosa accounts for 35% of all P. aeruginosa isolated from respiratory samples of patients with cystic fibrosis (CF). The usefulness of β-lactam antibiotics for treating CF, such as carbapenems and later generation cephalosporins, is limited by the developme...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-21101-x |